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ABSTRACT 
Background: Despite declining rates of cardiovascular disease (CVD) mortality in developed countries, 
lower socioeconomic groups continue to experience a greater burden of the disease.   There are now 
many evidence-based treatments and prevention strategies for the management of CVD and it is 
essential their impact upon the more disadvantaged is understood if socioeconomic inequalities in CVD 
are to be reduced.   
Aims: To determine whether key interventions for CVD prevention and treatment are effective among 
lower socioeconomic groups, to describe barriers to their effectiveness and the potential or actual 
impact of these interventions on the socioeconomic gradient in CVD.   
Methods:  Interventions were selected from four stages of the CVD continuum.  These included 
smoking reduction strategies, absolute risk assessment, cardiac rehabilitation, secondary prevention 
medications, and heart failure self-management programs. Electronic searches were conducted using 
terms for each intervention combined with terms for socioeconomic status (SES).  
Results: Only limited evidence was found for the effectiveness of the selected interventions among 
lower SES groups and there was little exploration of socioeconomic-related barriers to their uptake.  
Some broad themes and key messages were identified. In the majority of findings examined, it was 
clear that the underlying material, social and environmental factors associated with disadvantage are a 
significant barrier to the effectiveness of interventions.  
Conclusion: Opportunities to reduce socioeconomic inequalities occur at all stages of the CVD 
continuum.  Despite this, current treatment and prevention strategies may be contributing to the 
widening socioeconomic-CVD gradient. Further research into the impact of best-practice interventions 
for CVD upon lower SES groups is required.  
.Word count = 252 
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BACKGROUND  
Cardiovascular disease (CVD) is the leading health problem for most countries of the world, accounting 
for 30% of the global burden of disease in 2005.(1)  Socioeconomic inequalities in CVD are well 
established, and many studies report a gradient in the disease from the most to the least 
disadvantaged.(2)  Despite recent declines in age-adjusted CVD mortality rates in many developed 
countries, evidence suggests that this gradient is widening so that lower socioeconomic groups carry an 
increasingly disproportionate burden of disease.(3-5) 
The evidence-base to support interventions to prevent or treat CVD is arguably as robust as in any area 
of health.  These interventions are implemented across all stages of the disease continuum from those 
who are well through to those with chronic heart failure, and include population-based measures, those 
based on systems of care, and medical therapies (Figure 1).  Many of these interventions underpin 
current global strategies to stem the burden associated with CVD, and are described in numerous 
national and international position statements and guidelines as being “gold-standard” or best-practice. 
(6-9)  
 
It is known that some population-based prevention strategies are more accessible to the better educated 
(10) and that there are disparities in access to health care.(11) However, the combined and cumulative 
effect of these inequalities across the CVD continuum is largely unknown.(12) It is vital that the impact of 
CVD interventions upon lower SES groups is fully understood.  Unless they are at least equally effective 
among disadvantaged groups they will not reduce inequalities, and may indeed contribute to the 
widening socioeconomic gradient in CVD.  
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In this review, key interventions from each stage of the CVD continuum recommended by international 
policy or clinical guidelines are examined. A specific aim was to review evidence for the effectiveness of 
each of these interventions among lower SES groups.  We also aimed to determine whether 
socioeconomic barriers to their effectiveness have been identified; and to describe the potential or 
actual impact of these interventions on the social gradient in CVD.  In addition, we identify key 
messages from the evidence that provide direction for future research or public health policies so that 
they might contribute towards decreasing health inequalities.  
The specific interventions reviewed are:  
1. Smoking reduction strategies among the well population: Cigarette smoking is a major risk 
factor for CVD, and the World Health Organisation recommends a number of interventions to 
reduce its prevalence. (13)   Of these, we have reviewed: (i) raising the price of tobacco through 
increased taxation, considered an effective deterrent to smoking at a population level;(14) and 
(ii) nicotine replacement therapy (NRT), shown to be moderately effective in supporting 
smoking cessation within the general population.(15)  Because the cost of NRT is a potential 
barrier to its use, particularly among lower-income groups, (16, 17)   only studies of free or 
subsidised NRT were reviewed. 
2. Absolute risk assessment to identify those who are asymptomatic but at most risk: Most 
guidelines for the prevention of CVD currently recommend the use of absolute (or “global”) risk 
equations to identify asymptomatic people at high risk of CVD events. These equations are 
based on levels of the range of important cardiovascular risk factors, rather than a single 
elevated risk factor in isolation. (18)      
3. Secondary prevention medications and cardiac rehabilitation: We reviewed two evidence-
based interventions known to be highly effective at reducing morbidity and mortality following 
acute myocardial infarction (AMI): (i) secondary prevention pharmacotherapy, the combination 
of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors and HMGCoA reductase 
inhibitors (statins),  estimated together to potentially reduce the relative risk of subsequent 
major events after AMI by up to 75%; (19) and (ii) cardiac rehabilitation (CR), shown to reduce 
all-cause mortality by up to 47% following a cardiac event. (20)  
4. Heart failure self-management programs: In the end-stages, interventions target those with 
chronic disease such as heart failure. The aim of treatment is to reduce symptoms as well as 
hospitalisation rates and mortality. One important intervention is heart failure self-management 
programs. (21) These are generally delivered in the hospital or home and led by nurses, with 
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most utilising a multi-disciplinary team approach. The majority emphasise self-management 
strategies such as daily recording of body weight and self-adjustment of diuretic dose. 
 
METHODS 
Search Strategy 
For each selected intervention we searched Medline and Cochrane Libraries for studies published in 
English between 1 January 1996 and 31 October 2008, conducted in adult populations. Our search was 
limited arbitrarily to studies published after 1996 in order to include only contemporary evidence.  
Additional studies were identified through reference lists and citation searches. 
Keywords and Medical Subject Headings (MeSH) for each specific intervention were combined with 
keywords and MeSH terms for SES.  The latter included (but was not limited to) social class, education 
level, low-income, poverty, occupation, and health disparities.  Selected terms were considered to 
capture most approaches to the measurement of SES. (2)  
Study selection and inclusion criteria 
Titles and abstracts were examined for relevance by two independent reviewers. Potentially relevant 
studies were assessed against the inclusion criteria, and disagreement resolved through discussion.  
Studies were included if they used quantitative outcomes to examine the effectiveness of the particular 
intervention among groups or individuals according to SES. These outcomes were: a) For the two 
smoking interventions, changes in rates of smoking prevalence or consumption; b) For absolute risk 
equations, their predictive performance or changes in the proportion of people assessed at being at high 
risk of CVD;  c) For secondary prevention medications, cardiac rehabilitation and heart failure programs, 
outcomes included changes in mortality rates, further CVD events or hospital readmissions, changes in 
cardiovascular risk factors, or behavioural modification. 
Studies were also examined for any description or exploration of barriers to the uptake or effectiveness 
of the particular interventions among lower SES groups or individuals. 
 Exclusion Criteria 
Because CVD largely occurs in adults, we excluded studies of interventions among children and 
adolescents, in whom other specific factors may be operative.  We also excluded studies of sex or 
ethnic-related inequalities, unless participants were specifically described as being of lower SES.  
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Data extraction and synthesis 
The studies included in the review had heterogeneous design features, and variable outcome measures. 
As such, it was not possible to conduct quantitative analyses and a narrative synthesis of the data is 
presented.  
RESULTS 
We screened 517 article abstracts, identified 225 potentially eligible papers and included a final total of 
49 studies.  Further details of included studies are shown in Appendix I.  
Interventions aimed to reduce smoking in the well population – increasing cigarette prices 
through raised taxation, and subsidised NRT  
a. Evidence for effectiveness among lower SES groups 
Fifteen studies were identified that examined the effectiveness of increasing tobacco taxation as a 
means of reducing smoking among lower SES groups.  Most studies had a cross-sectional design, with 
the majority reporting that disadvantaged groups in both developed and developing countries are 
responsive to changes in the price of cigarettes.(22-33)   However, evidence from three studies conducted 
in New Zealand, the United States and Europe suggested that increasing tobacco taxes as a smoking 
cessation strategy had only a limited effect on lower SES groups, (34-36)    and in Vietnam, smokers with 
higher education were more likely than those with lower education to quit smoking as cigarette prices 
increased (37). 
A further fourteen studies that examined the effect of NRT by SES were identified, including five 
randomised controlled trials.(17, 38-41) All studies were conducted within developed countries, primarily the 
United States.  Most studies combined NRT with telephone-based support, and this strategy appeared 
to be effective at reducing smoking prevalence for up to 12 months in lower socioeconomic groups both 
at a community level, (41-44)  or when disadvantaged groups were specifically targeted.  (17, 38, 45-50)  
b. Barriers to effectiveness among lower SES groups 
The ready availability of cheaper tobacco, single cigarettes, or black-market sources. (32, 33, 51, 52) are 
described as barriers to the effectiveness of increased tobacco taxation among lower socioeconomic 
groups in the United States and northern Europe.  In Scotland, disadvantaged individuals described 
themselves as addicted and unable to quit despite higher prices. (52)    
In all of the studies reviewed above, NRT was either free or subsidised, addressing an important barrier 
to its uptake among lower-income groups. Despite this, qualitative studies from the United States found 
limited awareness of the availability of subsidised NRT, (53, 54) and the requirement for a physician 
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prescription was perceived as a barrier among Canadian Aboriginal participants.(55)  Other studies also 
found that low-income smokers described NRT as ineffective, primarily because of underlying factors 
that encouraged long-term smoking, such as anxiety, stress or living in a disadvantaged area. (53, 56, 57)  
c. Potential impact on socioeconomic inequalities in smoking 
Evidence shows varying effects of increasing tobacco taxes among lower socioeconomic groups in both 
developed and developing countries.  These differences may be due to the stage of the smoking 
epidemic in that country, or to the effect of other tobacco reduction interventions, (34, 58, 59) and suggest 
that disadvantaged people may be less responsive to increased taxation in certain settings compared to 
others. Additionally, lower SES groups are described as unfairly burdened by increased taxation, 
because their greater nicotine dependency means they will continue to smoke even if the cost is 
increased. (35, 56) The direct impact of tobacco taxation on socioeconomic inequalities in smoking is 
therefore unclear.  
Further, while the available evidence suggests that subsidised NRT is effective among lower SES 
groups in the short term, longer-term smoking cessation can be difficult to sustain because of the many 
underlying factors associated with socioeconomic disadvantage. It is likely that subsidised NRT will be 
most effective when part of a comprehensive strategy that includes other approaches to support 
continued cessation.  In England, educational differences in smoking rates are decreasing, (16, 60)  and 
this may be because broader policies such as price increases are supported by measures specifically 
directed to the disadvantaged, including the provision of subsidised NRT and cessation services in 
deprived areas. (16, 61)  Use of revenue raised from tobacco taxes to fund such targeted cessation 
strategies offers a further opportunity to decrease smoking inequalities.  (62)    
Interventions targeting those at high risk of CVD – The measurement of absolute risk 
a. Evidence for the effectiveness among lower SES groups 
The most commonly used absolute risk prediction equations are those derived from the Framingham 
cohort study, conducted in Massachusetts, USA.(63)   While these equations are known to perform 
differently in different populations and ethnic groups, they can be “recalibrated” using local incidence 
and risk factor distribution data.(63, 64) 
Three studies from the United Kingdom (UK) and Australia were identified that examined the 
performance of the Framingham equations among lower SES groups, with overall findings that their use 
leads to underprediction of risk in those who are socially disadvantaged. (65-67) New risk equations from 
the UK that include area-based SES measures have recently been developed, and it was found that the 
proportion of lower SES individuals appropriately identified as being at high risk was significantly 
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increased when using these new equations in comparison to the Framingham equations. (18, 68, 69) 
Adding a measure of lifetime material disadvantage to the Framingham equation in a Scottish cohort did 
not significantly improve its ability to discriminate between those at higher and lower risk of CVD, (70)  
b. Barriers to effectiveness among lower SES groups 
Few barriers to the effectiveness of absolute risk equations among lower SES groups have been 
reported, although it is known that such people are less likely to visit their family doctor for preventive 
reasons.  This limits the opportunities for CVD risk factor screening. (71)  Even when those at higher risk 
are identified, compliance with medications or lifestyle change is difficult because of the many pre-
existing financial and social barriers to health associated with disadvantage. (18)    The Framingham 
equations in particular require diagnostic tests which are not available in all situations, including the 
poorer rural areas of lower-income countries.   Accordingly, simple risk equations have been developed 
that require only history, blood pressure and urinalysis for use in these settings. (72)  
c. Potential impact on socioeconomic inequalities in CVD 
Lower socioeconomic groups have a greater risk of developing CVD than those with higher SES, (65) 
and the use of absolute risk equations in these populations is an opportunity to effectively identify and 
treat this risk. However, the Framingham equations, commonly used at present, do not take into account 
the excess risk associated with disadvantage.  New risk equations that include SES are a means of 
identifying population subgroups in whom the need for preventive treatment is greater and as such, 
could be considered to be more equitable. (18, 73)  It is also suggested that lowering the treatment 
threshold for disadvantaged individuals could help compensate for the extra risk conferred by lower 
SES. (66)    
Interventions targeting those with clinical manifestations of disease - combination 
pharmacotherapy for secondary prevention of CVD, and cardiac rehabilitation 
a. Evidence for effectiveness among lower SES groups  
Three studies were identified that examine the effectiveness of combination pharmacotherapy within 
different socioeconomic groups. Two European studies found that patients from lower SES classes 
achieved comparable risk factor control to those in higher classes, (74, 75)  and in Quebec, an increase in 
co-payment for cardiac medication among elderly patients did not adversely affect health outcomes, 
regardless of SES. (76) 
Four studies which examined the effectiveness of cardiac rehabilitation by socioeconomic groups were 
identified.(77-80) Overall, the evidence points to the potential for CR to be effective at modifying major risk 
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factors across all socioeconomic strata.(77, 79) A study from the United States found that medically 
indigent participants benefited as much from attendance at CR as more affluent patients, with similar 
improvements in exercise tolerance, and dietary and smoking behaviours.(79) This study was conducted 
in a small centre-based program with high staff: patient ratios and pre-arranged transportation.   
b. Barriers to effectiveness among lower SES groups 
Because of their higher risk of recurrent CVD events, prescribing rates for evidence-based medications 
should at least be similar and probably higher among disadvantaged populations. (81) However, many 
studies have shown that even in countries with subsidised medication there is either a negative 
association, (81-89) or no association (74, 90-95)  between socioeconomic disadvantage and prescribing of 
CVD medications. There is limited discussion of the reasons underlying these findings, although 
physicians may be more reluctant to prescribe if they perceive potential issues with compliance such as 
the cost of medications.(83, 87, 96) Disadvantaged patients may also have more co-morbidities, thereby 
limiting the medications they can be prescribed (for example, beta-blockers are relatively 
contraindicated in those with reversible airways disease).(96) 
Poor referral and attendance rates at CR are also associated with low income,(97, 98) low education(98, 99)  
and neighbourhood deprivation.(100, 101)  The reasons underlying this gradient have been well explored, 
and include barriers such as program cost, (102) and lack of transport.(103)  High levels of depression, 
common among socially disadvantaged adults(104) are shown to be  associated with non-attendance at 
CR.(102)  Attendance is also influenced by the strength of recommendation from the physician,(105)  who 
may be more reluctant to refer lower SES patients because of scepticism about their ability to make 
lifestyle changes.(102) Lack of knowledge about CR has also been seen in Indigenous Australians. (106) 
c. Potential impact on socioeconomic inequalities in CVD 
The available evidence suggests that while CR and combination pharmacotherapy are effective among 
lower SES groups, access-related barriers to both are significant.  Socioeconomic inequalities in rates of 
coronary revascularisation have also been described, (107, 108)  indicating an overall need for more 
research into ways to improve uptake of secondary prevention services and therapies among 
disadvantaged populations. The use of innovative approaches to address barriers to access is 
warranted.  For example, pre-arranged collection or home-based programs can address difficulties with 
transportation to CR programs. (79, 102)   
The polypill has also been proposed as a measure by which co-formulation of low-cost generic 
compounds might allow more equitable access to proven medications for primary and secondary 
prevention of CVD. (109)  This is of particular relevance to underdeveloped countries where availability of 
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medications is limited in poorer rural areas. (110) Modelling of findings from a recent randomised 
controlled trial in India suggested that use of a polypill for primary prevention could potentially reduce 
cardiovascular heart disease and stroke by 62% and 48% respectively. (111)  
Interventions targeting patients with chronic heart failure - Heart failure self-management (HFSM) 
programs  
a. Evidence for effectiveness among lower SES groups 
Five studies were identified which examined the effect of HFSM programs among disadvantaged 
populations in the United States.(112-116)  When delivered within lower SES groups, these programs were 
effective in reducing rehospitalisation and mortality rates and improving functional ability. One 
randomised controlled trial that compared lower with higher educated participants attending the same 
program found no education-related differences in subsequent cardiac events or rehospitalisation.(114)   
b. Barriers to effectiveness among lower SES groups 
Self-management of heart failure is complex, and people with lower levels of education and health 
literacy may be less able to effectively manage their disease than those who are better educated,(117)   
describing a lack of confidence in their ability to self-manage their condition.(118) Financial barriers have 
also been identified, including costs of medication and visits to health professionals.(114, 117)    
c. Potential impact on socioeconomic inequalities in heart failure outcomes 
Evidence from the United States shows that HFSM programs are effective at reducing both mortality 
and hospital readmission rates among lower SES groups with CHF.  It may be that the intensive and 
regular contact with health professionals reduces the social isolation commonly experienced by 
disadvantaged people, and encourages their adherence to medication and exercise regimens.(116, 119)  
Additionally, the multidisciplinary team approach of HFSM programs allows for a variety of treatment 
modalities to be utilised, which can be tailored to each patient’s lifestyle and resources. Programs that 
are creative in their approach (such as those that use teaching materials designed for those with lower 
education) are also likely to be successful.(112, 117) 
DISCUSSION 
This review has examined the effectiveness of key evidence-based interventions for the prevention and 
treatment of CVD within lower SES groups, identified barriers to their utilisation and effectiveness, and 
highlighted their potential or actual impact upon the socioeconomic gradient in CVD.  Overall, only 
limited evidence was found for the effectiveness of the interventions examined and there was little 
exploration of SES-related barriers to their uptake. This has significant implications for public health 
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policy. If these important interventions are not effective among the disadvantaged then these groups will 
continue to carry a disproportionate burden of CVD, and current best-practice itself may be contributing 
to the socioeconomic gradient in CVD.  Indeed, because CVD imposes a major economic burden in 
many countries, and much of this relates to hospitalisation or residential care, it can be argued that it 
makes sound economic sense to implement strategies particularly among those who carry the greatest 
burden of disease.  
What might work at decreasing the SES/CVD gradient? Key messages 
Key messages that are pertinent for future efforts to reduce CVD among disadvantaged groups are 
shown in Table 1.  
Our findings identify opportunities for intervention across all stages of the disease continuum, and 
illustrate the importance of both primary and secondary prevention strategies in reducing the burden of 
CVD among lower SES groups. It is important to note that the relative contribution of secondary 
prevention strategies to the poorer prognosis for lower SES groups is unclear. Some studies from India, 
the United States and Finland suggest that disparities in evidence-based treatments during and after 
hospital admission for AMI account for most of the socioeconomic gradient in CVD outcomes. (82, 85, 120)  
However, others have shown that these same treatments explain less of the social gradient than do 
clinical status and CVD risk factor profile on admission.(88, 121)    These findings imply that reducing social 
disparities in CVD will require more than just improved access to care,(82, 88) and point to the vital 
importance of effective primary prevention strategies at earlier stages of the disease continuum so that 
the cumulative burden of CVD among disadvantaged individuals is reduced.  One recommended 
approach to primary prevention is that of combining of community- or population-based interventions 
with those directed specifically to “high-risk” individuals. (122) If lower SES individuals are seen as “high-
risk” because of the extra risk conferred by socioeconomic disadvantage, then this combination 
approach offers an opportunity to reduce the gradient seen in major CVD risk factors. This strategy has 
been effective at reducing smoking prevalence in disadvantaged groups in the UK, and could equally be 
applied to other risk factors.  For example, community measures to increase physical activity levels 
through introducing local walking trails could be made more attractive by enhancing the safety of such 
trails within disadvantaged neighbourhoods.  Although outside the scope of this review, it is also  
recognised that early life disadvantage plays an important role in the development of the social gradient 
in CVD. (123)  Reducing risk factors and environmental exposures in children through population or 
community-based measures will therefore likely have an impact upon future CVD burden. (122) 
Limitations 
 12
While a limited number of interventions have been examined, those selected are known to have a 
significant impact upon CVD morbidity and mortality. Therefore we consider our findings are important in 
advancing knowledge and understanding about strategies to reduce CVD among disadvantaged groups.  
The available evidence was limited, and studies of poorer quality and small sample size were not 
excluded.  This may restrict the generalisability of our conclusions. We also acknowledge that the focus 
of this review is on developed countries.  This is primarily because evidence from the developing world 
remains limited, despite these countries carrying the greater burden of CVD. (122)  Further, while not all 
underdeveloped countries show an inverse socioeconomic gradient in CVD, this may change as they 
become more industrialised. For example, in India, there has been a transition over the last decade from 
a positive association between social advantage and CVD to an inverse one. This shift is thought to be 
due to several factors including increased urbanisation and greater uptake of health protective 
behaviours among the higher social classes. (124)  Therefore, while our findings may not have immediate 
relevance for these countries, they are likely to be important in the future.  
Exclusion of ethnic-related inequalities (unless specifically described as lower SES) may have also 
underestimated the full extent of inequalities in CVD, particularly in the context of increasing multi-
ethnicity within cities such as New York and London. The issue of ethnic-related differences in CVD is 
highly complex, and complicated by cultural and genetic factors. (125) Migrant groups in particular may be 
at greater risk because of interactions between genetic susceptibility and their new environment. (126) 
However, not all migrants or minority ethnic groups are from a lower SES background.  It has also been 
demonstrated that a substantial portion of the 10yr risk of CVD that was associated with ethnicity in the 
United States could be attributed to SES or geography. (125) In view of this complexity, and to limit the 
scope of the paper, we elected to include only ethnic minorities if they were identified as having low 
SES.   
CONCLUSION 
There are significant socioeconomic disparities in the uptake and delivery of key prevention and 
treatment strategies at all stages of the CVD continuum, and a paucity of evidence for their 
effectiveness among lower socioeconomic groups. Increasing this evidence-base will require greater 
research efforts and a concerted and coordinated approach across many sectors of society.(127)  While 
there will be little impact on CVD inequalities until the underlying determinants of health inequalities are 
addressed, policy makers and clinicians must recognise the importance of SES as an independent risk 
factor for disease, and seek ways of incorporating it into current best-practice management of CVD.  
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Table 1 Key messages from this review
Potential successes 
1. Combining population-based strategies with those specifically directed to disadvantaged groups may reduce 
the SES-smoking gradient.  
2. Heart failure self-management programs are effective among lower SES groups possibly because they allow 
for an intensive and personalised approach. 
Potential opportunities  
1. Creative and innovative approaches to improve uptake of interventions are needed, such as those that 
increase access (home-based cardiac rehabilitation programs), or those that remove cost (free NRT), or 
those that are tailored towards lower SES groups (heart failure self-management programs). 
2. Lower SES individuals could be more appropriately identified as being at high risk of CVD either through 
inclusion of SES into absolute risk equations, or by lowering their thresholds for treatment  
Future directions for policy makers and researchers 
1. Many barriers to the effectiveness and utilisation of CVD interventions in lower SES groups are directly 
related to the underlying factors associated with disadvantage. More efforts towards identification of these 
barriers are required.  
2. Approaches that have been shown to work among the disadvantaged need further research into the causes 
of their effectiveness, for example, reasons underlying the declines in educational inequalities in smoking in 
the UK.  
3. The increased burden of CVD associated with lower SES is likely to be cumulative. Emphasis must be on 
intervening as early as possible within the CVD continuum.  
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